Overview

Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily multiple-dose administration of odanacatib (MK0822).
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.